Mapp Biopharmaceutical Inc., a San Diego-based company with nine employees, has made international headlines for its role in developing an experimental Ebola treatment that may save the lives of two American aid workers.

ZMapp is a combination of two agents, made by Mapp with LeafBio in San Diego. One of the agents, MB-003, provided 100 percent protection to monkeys when given right after exposure to Ebola virus, even after symptoms developed. The other agent, ZMAb, is a combination drug that its developer says provided 100 percent survival in primates a day after exposure and 50 percent survival after two days.

In an interview with ABC News, the Mapp Biopharmaceutical President Larry Zeitlin, described ZMapp as a “cocktail of monoclonal antibodies” and said in an email that the company was “in the midst of an intense effort to help address the Ebola outbreak in West Africa.”

The two American missionary workers, Kent Brantly and Nancy Writebol, contracted the virus in Liberia. According to CNN’s sources, both Brantly's and Writebol’s conditions have improved since the drug was administered.